Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma
Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This multicenter, open-label trial will randomize participants with multiple myeloma to a
regimen of ibandronate or zoledronate in order to compare the incidence of nephrotoxicity,
measured as creatinine clearance (CrCl) reduction greater than (>) 30 percent (%) or an
absolute value of 30 milliliters per minute (mL/min) or lower.